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Targeted Testing and the Diagnosis of 
Latent Tuberculosis Infection and Tuberculosis Disease 
BACKGROUND 
In this module, you will learn about the diagnosis of TB disease and latent TB infection (LTBI), 
including targeted testing. Targeted testing is a TB control strategy that is used to identify people 
at high risk for developing TB disease who would benefit by treatment of LTBI, if detected. LTBI 
is diagnosed with the Mantoux tuberculin skin test (TST) or an interferon-gamma release assay 
(IGRA) such as the QuantiFERON®-TB Gold test (QFT-G). In most cases, TB disease is 
diagnosed with certain laboratory tests (bacteriologic examination); for patients who may have 
pulmonary TB disease, a chest x-ray is also useful for diagnosis. It is important to evaluate 
people who have symptoms of TB disease; if they are found to have TB disease, they need 
treatment to be cured and to avoid spreading TB to others. For this reason, the diagnosis of TB 
disease is crucial to controlling the spread of TB in homes and communities.
OBJECTIVES 
After working through this module, you will be able to 
1. 	 Identify high-risk groups for targeted testing. 
2. 	 Describe how to place, read, and interpret a Mantoux tuberculin skin test. 
3. 	 Describe how to interpret a QuantiFERON®-TB Gold test. 
4. 	 Discuss considerations (for example, false-positives, false-negatives 
and/or limitations) for using either the Mantoux tuberculin skin test or the 
QuantiFERON®-TB Gold test for diagnosing infection with 
Mycobacterium tuberculosis.
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Look for the following new terms in this module and in the glossary. 
acid-fast bacilli (AFB) – mycobacteria that 
when stained, retain color even after they have 
been washed in an acid solution; may be 
detected under a microscope in a stained smear 
anergy – the inability to react to a skin test
because of a weakened immune system, often 
caused by HIV infection or severe illness (see 
anergy testing)
anergy testing – giving skin tests using 
substances other than tuberculin; done in select 
situations to determine whether a person is 
anergic
antigen – protein substances that can produce 
an immune response (such as CFP-10, ESAT­
6, or those in PPD)
bacteriologic examination – tests done in a 
mycobacteriology laboratory to diagnose TB 
disease; includes examining a specimen under 
a microscope, culturing the specimen, and 
testing for drug susceptibility 
baseline skin test – a tuberculin skin test 
(TST) given to employees or residents in 
certain facilities when they start their job or 
enter the facility (see TB testing program and 
two-step testing) 
BCG – bacille Calmette-Guérin (BCG), a 
vaccine for TB disease that is used in many 
countries but rarely used in the United States; 
may cause a false-positive reaction to the TST 
but does not affect QuantiFERON®-TB Gold
test (QFT-G) results
boosted reaction – a positive reaction to a 
TST, due to a boosted immune response from a 
skin test given up to a year earlier; occurs in 
people who were infected a long time ago and 
whose ability to react to tuberculin has 
lessened. Two-step testing is used in TB 
testing programs to tell the difference between 
boosted reactions and reactions caused by 
recent infection (see booster phenomenon and 
two-step testing) 
booster phenomenon – a phenomenon in 
which people (especially older adults) who are 
skin tested many years after becoming infected 
with M. tuberculosis may have a negative 
reaction to an initial TST, followed by a 
positive reaction to a TST given up to a year 
later; this happens because the first TST boosts 
the immune response. Two-step testing is used 
in TB testing programs to tell the difference 
between boosted reactions and reactions 
caused by recent infection (see two-step 
testing) 
bronchoscopy – a procedure used to obtain 
pulmonary secretions or lung tissue with an 
instrument called a bronchoscope; used only 
when patients cannot cough up sputum on their 
own and an induced specimen cannot be 
obtained 
cavity – a hollow space within the lung, visible 
on a chest x-ray, that may contain many 
tubercle bacilli; often occurs in people with 
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CFP-10 – one of the antigens used in the 
QFT-G that is found in M. tuberculosis strains
clinician – a physician, physician’s assistant, 
or nurse
colonies – groups of mycobacteria that have 
grown in a culture
control – a standard of comparison for 
checking or verifying the results of an 
experiment. In the QFT-G, the substances 
mitogen and saline are the controls
culture – to grow organisms on media 
(substances containing nutrients) so that they 
or the product of this process can be identified; 
a positive culture for M. tuberculosis contains 
tubercle bacilli, whereas a negative culture 
contains no detectable tubercle bacilli
drug susceptibility pattern – the list of drugs 
to which a strain of tubercle bacilli is 
susceptible and to which it is resistant
erythema – redness around the site of the 
injection when a TST is done; erythema is not 
considered when the reaction size is measured, 
because redness does not indicate that a person 
has TB infection 
ESAT-6 – one of the antigens used in the 
QFT-G that is found in M. tuberculosis strains
exposure to TB – time spent with or near 
someone who has infectious TB disease 
false-negative reaction – a negative reaction 
to the TST in a person who has TB infection; 
may be caused by HIV or other 
immuncompromising diseases, 
immunosuppressive drugs, a live-virus 
vaccination, recent infection (within the past 
10 weeks), or very young age (younger than 6 
months old) 
false-positive reaction – a positive reaction to 
the TST in a person who does not have TB 
infection; may be caused by infection with 
nontuberculous mycobacteria or by vaccination 
with BCG
gastric washing – a procedure done by 
inserting a tube through the patient’s nose and 
passing it into the stomach; may be useful for 
obtaining a specimen for culture from children, 
who produce little or no sputum when they 
cough 
heparin – an anti-clotting agent added to 
patient’s blood samples for conducting a 
QFT-G 
induced sputum – sputum that is obtained by 
having the patient inhale a saline (salt water) 
mist, causing the patient to cough deeply; this 
procedure is used to help patients cough up 
sputum if they cannot do so on their own
induration – swelling that can be felt around 
the site of injection after a TST is done; the 
reaction size is the diameter of the swollen 
area, measured across the forearm
infiltrate – a collection of fluid and cells in the 
tissues of the lung; visible on a chest x-ray in 
people with pulmonary TB disease
interferon-gamma (IFN-γ) – protein that is 
normally produced by the body in response to 
infection; the QFT-G results are based on how 
much IFN-γ is released in response to antigens 
mixed with a patient’s blood sample 
interferon-gamma release assay (IGRA) – a 
type of blood test that measures a person’s 
immune reactivity to M. tuberculosis. In the 
U.S., QuantiFERON®-TB Gold and the 
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isolate – a group of organisms isolated or 
separated from a specimen; in an 
M. tuberculosis isolate, the organisms have 
been grown in culture and identified as 
M. tuberculosis
malaise – a feeling of general discomfort or 
illness 
Mantoux tuberculin skin test (TST) – a 
method of testing for TB infection; done by 
using a needle and syringe to inject 0.1 ml of 5 
tuberculin units of liquid tuberculin between 
the layers of the skin (intradermally), usually 
on the forearm; the reaction to this test, usually 
a small swollen area (induration), is measured 
48 to 72 hours after the injection and is 
interpreted as positive or negative depending 
on the size of the reaction and the patient’s risk 
factors for TB
media – substances containing special 
nutrients and used for growing cultures of 
bacteria found in specimens
medical history – the part of a patient’s life 
history that is important for diagnosing and 
treating TB infection or disease, including 
history of exposure, symptoms, previous 
diagnosis of TB infection or disease, and risk 
factors for TB disease
multiple-puncture test – a type of tuberculin 
skin test done by puncturing the skin of the 
forearm with a set of short prongs or tines to 
inject tuberculin (for example, Tine test); 
although easy to give and convenient, these 
tests are not accurate and should not be used to 
determine whether a person has TB infection
mycobacteriology laboratory – a laboratory 
that deals specifically with M. tuberculosis and 
other mycobacteria 
nucleic acid amplification (NAA) – a
technique that amplifies (copies) DNA and 
RNA segments, in to order to directly identify
microorganisms in sputum specimens
polymerase chain reaction (PCR) – a 
technique used to copy small segments of 
DNA 
PPD (purified protein derivative) – antigens 
such as the type of tuberculin used in the TST 
(see antigen) 
PPD skin test – a tuberculin skin test that uses 
PPD tuberculin 
QuantiFERON®-TB Gold (QFT-G) – a 
blood test used for diagnosing infection with 
M. tuberculosis. The QFT-G measures a 
patient’s immune reactivity to M. tuberculosis
resistant – an organism’s ability to grow 
despite the presence of a particular drug
skin test conversion – a change in a skin test 
reaction from negative to positive between 
testing intervals 
smear – a specimen that has been smeared 
onto a glass slide, stained, washed in an acid 
solution, and then placed under the microscope 
for examination; used to detect acid-fast bacilli 
in a specimen
sputum – phlegm from deep in the lungs, 
collected in a sterile container for processing 
and examination
susceptible – an organism’s abilty to be killed 
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symptoms of TB disease – noticeable 
conditions caused by TB disease. The 
symptoms of pulmonary TB disease include 
coughing, pain in the chest when breathing or 
coughing, and coughing up sputum or blood. 
The general symptoms of TB disease 
(pulmonary or extrapulmonary) include weight 
loss, fatigue, malaise, fever, and night sweats. 
The symptoms of extrapulmonary TB disease 
depend on the part of the body that is affected 
by the disease 
targeted testing – a TB control strategy to 
identify persons at high risk for latent TB 
infection and persons at high risk for 
developing TB disease who would benefit 
from treatment 
TB testing program – a program in which 
employees and residents of a facility are 
periodically tested for TB; done to identify 
people who have TB infection and possibly TB 
disease and to determine whether TB is being 
transmitted in the facility
TST (tuberculin skin test) – see Mantoux 
tuberculin skin test
tuberculin – a substance made from tubercle 
bacilli that have been killed by heating; used to 
determine whether a person has TB infection. 
Tuberculin is not a vaccine
tuberculin unit – a standard strength of 
tuberculin used in the United States and 
Canada; a strength of 5 tuberculin units is used 
for the Mantoux TST
two-step testing – a strategy used in TB 
testing programs to distinguish a boosted 
reaction (caused by TB infection that occurred 
many years before the skin test) from a 
reaction caused by recent infection. If a person 
has a negative reaction to an initial skin test, a 
second test is given 1 to 3 weeks later; a 
positive reaction to the second test probably 
represents a boosted reaction, not recent 
infection. Two-step testing is used in many TB 
testing programs for skin testing employees 
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. . . . . . . . . . . . . . . . . . . . . . . . 
A decision to test is a 
decision to treat. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People who are not at high 
risk for LTBI generally 
should not be tested. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Targeted testing is the TB control strategy that is used to 
identify and treat persons who are at high risk for LTBI or 
at high risk for developing TB disease once infected with 
M. tuberculosis. Identifying persons with LTBI is 
important to the goal of TB elimination because LTBI 
treatment can prevent these persons from developing TB 
disease and thereby stop the further spread of TB to others. 
Thus, during routine patient evaluations, health care 
providers should identify and test persons who are at high 
risk for TB. However, TB testing activities should be done 
only when there is a plan for follow-up care to evaluate and 
treat all individuals diagnosed with LTBI or TB disease. 
Healthcare agencies or other facilities should consult with 
the local health department before starting a TB testing 
program to make sure that any person whose test result is 
positive will have access to follow-up care.  
People who are not at high risk for LTBI generally should 
not be tested. Testing in low-risk populations can take 
resources away from other important activities. Also, 
positive test results in low-risk populations are sometimes 
inaccurate. There, however, may be instances in which 
health care providers are asked to test individuals who are 
not necessarily regarded as high risk (for example, daycare 
center workers, teachers, and college students).  
Identifying High-Risk Groups for TB Testing: 
High-risk groups can be divided into two categories:  
 People who are at high risk for becoming infected 
with Mycobacterium tuberculosis 
 People who are at high risk for developing TB 
































. . . . . . . . . . . . . . . . . . . . . . . . 
Flexibility should be used in 
defining high-risk groups for 
testing. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Latent Tuberculosis Infection and Tuberculosis Disease 
Targeted Testing and the Diagnosis of 
Flexibility should be used in defining high-risk groups for 
testing. Since the epidemiology of TB can change, the risk 
of LTBI or TB disease among groups may change over 
time. Groups that are currently identified as being at low-
risk may later be considered high priority. Moreover, 
because of the differences in populations from one 
community to another, definitions of high risk should be 
made at the local (city, county, or state) level according to 
local demographics and TB epidemiology. 
In general, however, high-risk groups listed in both 
categories of Table 3.1 should be tested. 
Table 3.1 
Groups at High Risk for LTBI and TB Disease 
People at High Risk for 
Becoming Infected with M. tuberculosis 
People at High Risk for TB Disease  
after M. tuberculosis Infection 
 Close contacts of people known or  People living with HIV 
suspected to have TB  People recently infected with 
 People, including children, who have M. tuberculosis (within the past 2 
come to the United States (within the years) 
last 5 years) from areas of the world  People with medical conditions 
where TB is common (for example, known to increase the risk for TB 
Asia, Africa, Russia, Eastern Europe, 
or Latin America) – silicosis 
– diabetes mellitus 
 Low-income groups with poor access – severe kidney disease
to health care, including homeless – certain types of cancer  
people – certain intestinal conditions 
 People who inject illegal drugs – organ transplant 
 People who live or work in high-risk – immunosuppressive therapy (including 
residential settings (for example, prolonged use of oral or intravenous 
nursing homes, homeless shelters, or 
correctional facilities)
corticosteroids, and tumor necrosis 
factor-alpha [TNF-α] antagonists)  
 Health care workers who serve high-
risk clients 
– low body weight 
People who inject illegal drugs 
 High-risk racial or ethnic minority  Infants and children younger than 4 
populations, as locally defined years 
 Infants, children, and adolescents 
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Diagnosis of LTBI 
. . . . . . . . . . . . . . . . . . . . . . . . 
The TST can be used to 
determine whether a person 
has LTBI. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Tuberculin is not a vaccine. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Currently, the available methods of testing for 
M. tuberculosis infection are the Mantoux tuberculin skin 
test (TST) and the interferon-gamma release assays 
(IGRA) such as the QuantiFERON®-TB Gold test (QFT­
G). 
The Mantoux Tuberculin Skin Test (TST) 
The TST is used to determine if a person is infected with 
M. tuberculosis. In this test, a substance called tuberculin
is injected into the skin. Tuberculin contains antigens used 
for diagnosing TB infection; it is not a vaccine. An antigen 
is a protein substance that can produce an immune 
response. Tuberculin is made from proteins derived from
tubercle bacilli that have been killed by heating. In most 
people who have TB infection, the immune system will 
recognize the tuberculin because it is similar to the tubercle 
bacilli that caused infection. This will cause a reaction to 
the tuberculin at the site of the injection. Tuberculin used 
for the skin test is also known as purified protein 
derivative, or PPD. For this reason, the TST is sometimes 
called a PPD skin test. 
Administering the TST 
The TST is given by using a single dose disposable 
tuberculin syringe to inject 0.1 ml of 5 tuberculin units of 
liquid tuberculin between the layers of the skin 
(intradermally), on the forearm (Figure 3.1). A tuberculin 
unit is a standard strength of tuberculin. When giving the 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Most people with TB 
infection have a positive 
reaction to the tuberculin. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The reaction is an area of 
induration, or swelling, 
around the site of the 
injection. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The Mantoux TST is the 
preferred type of TB skin 
test. 
. . . . . . . . . . . . . . . . . . . . . . . . 
A patient’s forearm should be examined by a trained health 
care worker 48 to 72 hours after the tuberculin is injected. 
Health care workers should not ask patients to read their 
own skin test results. Most people with TB infection will 
have a positive reaction to the tuberculin. The reaction is an 
area of induration (swelling that can be felt) around the 
site of the injection. The diameter of the indurated area is 
measured in millimeters across the forearm (Figure 3.2); 
erythema (redness) around the indurated area is not 
measured, because the presence of erythema does not 
indicate that a person has TB infection (Figure 3.3).  
In the past, multiple-puncture tests (for example, the Tine 
test) were a popular skin testing method for TB; however, 
the multiple-puncture test is no longer recommended. The 
multiple-puncture tests are done by puncturing the skin of 
the forearm with a device having a set of short prongs or 
tines coated with tuberculin. However, since the amount of 
tuberculin that actually enters the skin cannot be measured, 
multiple-puncture tests are not reliable and should not be 
used. Because the amount of tuberculin can always be 
measured during a Mantoux TST, this type of test is more 
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Figure 3.1 Giving the Mantoux TST. 
Figure 3.3 The erythema is being measured. 
This is INCORRECT. 
Figure 3.2 Only the induration is being 
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Study Questions 3.1 – 3.2 
3.1 What is the TST used for?
3.2 How is the Mantoux TST given?
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Study Questions 3.3 – 3.5 
3.3 With the TST, when is the patient’s arm examined?
3.4 How is the induration measured? 
3.5 Why is the Mantoux TST preferable to multiple-puncture tests?
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Interpreting the Reaction
. . . . . . . . . . . . . . . . . . . . . . . . Interpreting a TST reaction depends on the size of the Interpretation of a reaction to induration and the person’s risk factors for TB (Table 3.2). a TST depends on the size of 
the induration and on the An induration of 5 or more millimeters is considered a 
person’s risk factors for TB. positive reaction for the following people: 
. . . . . . . . . . . . . . . . . . . . . . . .  People living with HIV 
 Recent close contacts of people with infectious TB
	 People with chest x-ray findings suggestive of 
previous TB disease 
 People with organ transplants 
	 Other immunosuppressed patients (for example, 
patients on prolonged therapy with corticosteroids, 
equivalent to 15mg per day or more of prednisone 
for at least 1 month, or those taking TNF-α
antagonists) 
An induration of 10 or more millimeters is considered a 
positive reaction for the following people: 
	 People who have recently come to the United States 
(within the last 5 years) from areas of the world 
where TB is common (for example, Asia, Africa, 
Russia, Eastern Europe, or Latin America) 
 People who inject illegal drugs 
	 People who live or work in high-risk congregate 
settings (for example, nursing homes, homeless 
shelters, or correctional facilities) 
 Mycobacteriology laboratory workers 
	 People with medical conditions, other than HIV, that 
increase the risk for developing TB disease (see 
Table 3.1) 
 Children younger than 4 years 
	 Infants, children, or adolescents exposed to adults
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. . . . . . . . . . . . . . . . . . . . . . . . 
An induration of 15 or more 
millimeters is considered a 
positive reaction for people 
with no known risk factors 
for TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
An induration of 15 or more millimeters is considered a 
positive reaction for people with no known risk factors for 
TB. However, targeted testing should be done only in 
high-risk groups since a positive test result in low-risk 
groups can be inaccurate.
Most people who have a positive TST reaction will 
usually have a positive reaction every time they are tested, 
regardless of whether they receive treatment. This is 
because the TST detects the immune response to 
tuberculin, not the presence of tubercle bacilli in the body. 
Thus the TST should not be performed on a person who 
has a documented history of either a positive TST result 
or treatment for TB disease. 
Interpreting the TST Reaction for Occupational 
Exposure 
For people who may be exposed to TB on the job (such 
as health care workers and staff of nursing homes or 
correctional facilities), the interpretation of the TST 
reaction as positive or negative depends on  
 The employee’s individual risk factors for TB 
 The risk of exposure to TB in the person’s job 
Therefore, in facilities where the risk of exposure to TB is 
very low, 15 or more millimeters of induration may be 
considered a positive reaction for employees with no other 
risk factors for TB. In facilities where TB patients receive 
care, 10 or more millimeters of induration may be 
considered a positive reaction for employees with no other 
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Table 3.2 
Interpreting the TST Reaction 
5 or more millimeters 10 or more millimeters 15 or more millimeters
An induration of 5 or more An induration of 10 or more An induration of 15 or 
millimeters is considered millimeters is considered positive more millimeters is 
positive for for considered positive for 
 People living with  People who have come to  People with no 
HIV the U.S. within the last 5 known risk 
 Recent contacts of years from areas of the factors for TB
persons with world where TB is 
infectious TB common (for example, 
 People who have 
previously had TB 
disease 
 Patients with organ 
transplants and other 
immunosuppressed 
Asia, Africa, Eastern 
Europe, Russia, or Latin 
America) 
 People who inject illegal 
drugs 
 Mycobacteriology lab 
patients (including workers 
patients taking a  People who live or work in 
prolonged course of high-risk congregate 
oral or intravenous settings 
corticosteriods or  People with certain medical 
TNF-α antagonists) conditions that place them 
at high risk for TB 
(silicosis, diabetes mellitus, 
severe kidney disease, 
certain types of cancer, and 
certain intestinal
conditions) 
 Children younger than 4 
years 
 Infants, children, and 
adolescents exposed to 
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Study Questions 3.6 – 3.7 
3.6 	 What two factors determine the interpretation of a skin test reaction as positive 
or negative? What additional factor is considered for people who may be
exposed to TB on the job?
3.7 	 For which groups of people is 5 or more millimeters of induration considered a 
positive reaction? Name four. 
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Study Questions 3.8 – 3.9 
3.8 	 For which groups of people is 10 or more millimeters of induration considered a 
positive reaction? Name seven. 
3.9 	 For which group of people is 15 or more millimeters of induration considered a 
positive reaction?
Answers to study questions are on pages 71 – 77. 
Case Study 3.1 
Which of the following patients have a positive TST reaction? Circle the best 
answer(s). 
a) Mr. West, 36 years old, HIV infected, 8 mm of induration  
b) Ms. Hernandez, 26 years old, native of Mexico, 7 mm of induration 
c) Ms. Jones, 56 years old, has diabetes, 12 mm of induration 
d) Mr. Sung, 79 years old, resident of a nursing home, 11 mm of 
induration 
e) Mr. Williams, 21 years old, no known risk factors, 13 mm of 
induration 
f) Ms. Marcos, 42 years old, chest x-ray findings suggestive of previous 
TB, 06 mm of induration 
g) Ms. Rayle, 50 years old, husband has pulmonary TB, 9 mm of 
induration 
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. . . . . . . . . . . . . . . . . . . . . . . . 
False-positive reactions can 
be caused by infection with 
nontuberculous mycobacteria 
or vaccination with BCG. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People who have a positive 
reaction should be further 
evaluated for LTBI or TB 
disease, even if they were 
vaccinated with BCG. 
. . . . . . . . . . . . . . . . . . . . . . . . 
False-Positive Reactions 
The TST is a valuable tool, but it is not perfect. Several 
factors can cause people to have a positive reaction even if
they do not have TB infection. This is called a false-
positive reaction. 
The causes of false positive reactions may include, but are 
not limited to, the following: 
	 Infection with nontuberculous mycobacteria (NTM) 
(mycobacteria other than M. tuberculosis)
	 BCG vaccination 
	 Administration of incorrect antigen 
	 Incorrect measuring or interpretation of the TST 
reaction 
Infection with NTM can sometimes cause a false positive 
reaction to the TST. Another cause of a false positive 
reaction is BCG (bacille Calmette-Guérin), a vaccine for 
TB disease that is used in many countries. BCG, however, 
is rarely used in the United States because studies have 
shown that it is not completely effective. People who have 
been vaccinated with BCG may have a positive reaction to 
the TST even if they do not have TB infection. 
However, there is no reliable way to distinguish a positive 
TST reaction caused by vaccination with BCG from a 
reaction caused by true TB infection. When using the TST, 
people who have been vaccinated with BCG should always 
be further evaluated for LTBI or TB disease as if they were 
not vaccinated with BCG. 
A false-positive reaction may also occur if an incorrect 
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Study Questions 3.10 – 3.11 
3.10 	 Name four factors that can cause false-positive reactions to the TST. 
3.11 	 Is there a reliable way to distinguish a positive tuberculin reaction caused by 
vaccination with BCG from a reaction caused by true TB infection?
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Case Study 3.2 
A 30-year-old man who recently immigrated from India is given a TST and found 
to have 14 millimeters of induration. He reports that he was vaccinated with BCG 
as a child. He also says that his wife was treated for pulmonary TB disease last 
year. 
 How should this man’s results be interpreted? 
 What factors make it more likely that this man’s positive reaction is 
due to TB infection? 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Anergy is the inability to
react to skin tests because of 
a weakened immune system. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People who do not react to 
any of the substances used 
for anergy testing (including 
tuberculin) are considered 
anergic. 
. . . . . . . . . . . . . . . . . . . . . . . . 
False-Negative Reactions 
Some people have a negative reaction to the TST even 
though they have TB infection. This is called a false-
negative reaction. The reasons for these false-negative 
reactions may include, but are not limited to the following: 
 Anergy 
 Recent TB infection (within the past 8-10 weeks)
 Very young age (younger than 6 months) 
 Recent live-virus measles or smallpox vaccination 
 Incorrect method of giving the TST  
	 Incorrect measuring or interpretation of TST 
reaction 
A common cause of false-negative reactions is anergy. 
Anergy is the inability to react to skin tests because of a 
weakened immune system. Many conditions, such as HIV 
infection, cancer, measles or other viral infections, or 
severe TB disease itself, can weaken the immune system
and cause anergy. HIV infection is an important cause of 
anergy. 
Anergy testing in conjunction with skin testing is no 
longer routinely recommended as a part of TB testing; 
however, in some situations anergy testing may be used to 
guide decisions regarding therapy for patients. Anergy 
testing can be done by giving skin tests using substances 
other than tuberculin. The recommended substances for 
anergy testing include mumps, Candida (a type of fungus), 
or tetanus extracts. Most healthy people will have a skin 
test reaction to one or more of these substances. 
People who do not react to any of the substances, including 
tuberculin, are considered anergic. People who have a 
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. . . . . . . . . . . . . . . . . . . . . . . . 
It takes 2 to 8 weeks after TB 
infection for the body’s 
immune system to be able to 
react to tuberculin. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Because their immune 
systems are not yet fully 
developed, children younger 
than 6 months old may have a 
false-negative reaction to the 
TST. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Any patient with symptoms 
of TB should be evaluated for 
TB disease, regardless of his 
or her skin test reaction. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Another cause of false-negative reactions is recent TB 
infection (infection within the past 8 to 10 weeks). It can 
take 2 to 8 weeks after TB infection for the body’s immune 
system to be able to react to tuberculin and for the infection 
to be detected by the TST. For this reason, it is 
recommended that close contacts of someone with 
infectious TB disease who have a negative reaction to the 
TST be retested 8 to 10 weeks after the last time they were 
in contact with the person who has TB disease.  
A third cause of false-negative reactions is very young 
age. Because their immune systems are not yet fully 
developed, children younger than 6 months may have a 
false-negative reaction to the TST. 
Vaccination with live viruses may also lead to a false-
negative reaction. The Advisory Committee on 
Immunization Practices recommends that skin testing be 
done on either the same day as vaccination with live-virus 
measles vaccine or 4 to 6 weeks after vaccination to 
prevent possible false-negative reactions. Also, skin testing 
should not be done until at least 1 month after a smallpox 
vaccination.
A false-negative reaction may also occur when the TST is 
given incorrectly or the results are not measured or 
interpreted properly. 
Both false-positive and false-negative reactions to the TST 
are summarized in Table 3.3. 
Any patient with symptoms of TB should be evaluated 
for TB disease, regardless of his or her TST reaction. In 
fact, people with symptoms of TB should be evaluated for 
TB disease right away, at the same time that the TST is 
given. TB symptoms and the diagnosis of disease are 
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False-Positive and False-Negative Reactions to the TST 
Type of 
Reaction Possible Cause People at Risk 
False-positive Nontuberculous mycobacteria 
(NTM) 
People infected with NTM 
BCG vaccination People vaccinated with BCG 
Administering of incorrect antigen Any person being tested 
Incorrect interpretation of TST result Any person being tested 
False-negative Anergy HIV-infected people, other people 
with weakened immune systems, 
severe TB disease, and some viral 
illness (e.g., measles and chicken 
pox) 
Recent TB infection People infected with 
M. tuberculosis within the past 8 
to 10 weeks 
Very young age Children younger than 6 months  
Recent live-virus measles or small 
pox vaccination 
Any person who will be or 
recently received a live-virus 
vaccination 
Incorrect method of giving TST Any person being tested 
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Study Questions 3.12 – 3.14 
3.12 	 Name six factors that can cause false-negative reactions to the TST. 
3.13 	 What is anergy?
3.14 	 After TB germs have been transmitted to someone, how long does it take before 
TB infection can be detected by the TST?
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Study Question 3.15 
3.15 	 What should be done if a patient has a negative TST result, but has symptoms of 
TB disease? 
Answers to study questions are on pages 71 – 77. 
Case Study 3.3 
Mr. Bell comes to the TB clinic for a TST. He believes that he has been exposed to 
TB, and he knows he is at high risk for TB because he is HIV infected. He is given 
a TST, and his reaction is read 48 hours later as 0 millimeters of induration. 
 What are three ways to interpret this result?
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. . . . . . . . . . . . . . . . . . . . . . . . 
Certain facilities have TB
testing programs, in which 
employees and residents are 
periodically given TSTs. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
In a TB testing program, 
employees or residents are 
skin tested when they start 
their job or enter the facility; 
repeat testing is done at 
regular intervals thereafter. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
In order to detect TB 
transmission and identify 
people who have skin test 
conversions, accurate 
information must be obtained 
for every employee’s skin 
tests. 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB Testing Programs, the Booster Phenomenon, and 
Two-Step Testing  
Many residential facilities, health care facilities, and other 
settings have TB testing programs. This means that 
employees and residents are periodically given TSTs. The 
purposes of the testing programs are to  
	 Identify people who have LTBI and possibly TB 
disease, so that they can be given treatment as 
needed 
	 Determine whether TB is being transmitted in the 
facility 
In a TB testing program, employees or residents are TB 
tested when they start their job or enter the facility. If they 
are using a TST, this is called the baseline skin test. If 
they have a negative TST reaction, they may be retested at 
regular intervals thereafter. In some facilities, repeat testing 
should be done at least once a year. For more information 
on TB testing programs at health care and residential 
facilities, please refer to Module 5, Infectiousness and 
Infection Control. 
Employees or residents whose skin test reaction converts 
from negative to positive between testing intervals have 
probably become infected with M. tuberculosis. These skin 
test conversions may indicate that TB is being transmitted 
in the facility. People with skin test conversions are at high 
risk of developing TB disease because they were infected 
with M. tuberculosis relatively recently (within the past 2 
years). (See Module 1, Transmission and Pathogenesis of 
Tuberculosis.) In order to detect TB transmission and 
identify people who have skin test conversions, accurate 
information must be obtained for every employee’s 
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. . . . . . . . . . . . . . . . . . . . . . . . 
The booster phenomenon can 
affect the accuracy of the 
baseline skin test. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The booster phenomenon 
happens when a skin test 
boosts the ability of the 
immune system to react to 
tuberculin. 
. . . . . . . . . . . . . . . . . . . . . . . . 
One factor that can affect the accuracy of the baseline skin 
test is the booster phenomenon. The booster phenomenon 
happens because in some people who have TB infection, 
the ability to react to tuberculin lessens over time. When 
these people are skin tested many years after they became
infected with M. tuberculosis, they may have a negative 
reaction. However, if they are tested again within a year of 
the first test, they may have a positive reaction. This is 
because the first skin test “jogged the memory” of the 
immune system, boosting its ability to react to tuberculin. 
It may appear that these people were infected between the 
first and second skin tests (recent TB infection). Actually, 
the second, positive reaction is a boosted reaction (due to 
TB infection that occurred a long time ago). The booster 
phenomenon occurs mainly among older adults. The 
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A person becomes infected with M. tuberculosis. 
As the years pass, the person’s
ability to react to tuberculin 
lessens. 
The person has a negative 
reaction because he or she has
a lessened ability to react 
to tuberculin. 
However, this skin test “jogs
the memory” of the immune 
system to recognize and react 
to tuberculin. 
The person is skin tested. 
The person is skin tested again. 
Up to 1 year later
(For this example, we assume
that the person was NOT 
exposed to TB during this time.) 
The person has a positive 
reaction. This is a boosted 
reaction due to TB infection 
that occurred a long time ago,
not during the time between 
the two skin tests. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Two-step testing is a strategy 
for telling the difference 
between boosted reactions 
and reactions caused by 
recent infection. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Two-step testing is used in 
many TB testing programs 
for skin testing employees 
when they start their job.
. . . . . . . . . . . . . . . . . . . . . . . . 
The booster phenomenon can present a problem in TB 
testing programs. This is because a negative reaction to the 
baseline skin test, followed by a positive reaction to a 
subsequent skin test that is given up to a year later, may be 
caused by either 
	 Recent TB infection in a person who was NOT 
infected at the time of the baseline skin test, or  
	 A boosted reaction in a person who WAS already 
infected before the baseline skin test
To avoid misinterpretation, a strategy has been 
developed for telling the difference between boosted 
reactions and reactions caused by recent infection. This 
strategy, called two-step testing, should be used for the 
initial skin testing of persons who will be retested
periodically, such as health care workers.  
If a person has a negative reaction to an initial skin test, he 
or she is given a second test 1 to 3 weeks later. 
	 If the reaction to the second test is positive, it 
probably is a boosted reaction (due to TB infection 
that occurred a long time ago). 
	 If the reaction to the second test is negative, the 
person is considered uninfected. In this person, a 
positive reaction to a skin test given later on will 
probably be due to recent infection and be 
considered a skin test conversion. 
Thus, because it provides accurate information about each 
employee’s baseline skin test reaction, two-step testing is 
used in many TB testing programs for employees when 
they start their job. In particular, two-step testing is often 
used in hospitals and nursing homes. The procedure for 
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Baseline skin test 
Reaction 
Negative Positive 
Retest 1-3 weeks later Person probably has TB infection 
Negative Positive 
The reaction is 
considered a 
boosted reaction 
(due to TB infection 
that occurred a long 
time ago) 
Person probably
does NOT have 
TB infection 
Repeat at regular Retesting not
intervals; a necessary 
positive reaction
will probably be 
due to a recent 
TB infection  
 Figure 3.5 Two-step testing.
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Study Questions 3.16 – 3.19 
3.16 What is the booster phenomenon?
3.17 What is the purpose of two-step testing?
3.18 In what type of situation is two-step testing used? 
3.19 How is two-step testing done?
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Case Study 3.4 
Ms. Wilson is a 60-year-old nurse. When she started a job at the local hospital, she 
was given a TST, her first test in 25 years. Her reaction was read 48 hours later as 
0 millimeters of induration. Six months later, she was retested as part of the TB 
testing program in the unit where she works. Her skin test reaction was read 48 
hours later as 11 millimeters of induration. 
 What are two ways to interpret this result? 
Answers to case study questions are on pages 78 – 81. 
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. . . . . . . . . . . . . . . . . . . . . . . 
The QFT-G is used to help 
diagnose M. tuberculosis
infection.
. . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . 
Before conducting a QFT-G, 
arrangements should be 
made with a qualified 
laboratory. 
. . . . . . . . . . . . . . . . . . . . . . . 
The QuantiFERON®-TB Gold Test 
The QuantiFERON®-TB Gold (QFT-G) is a blood test 
referred to as an interferon-gamma release assay 
(IGRA). IGRAs are blood tests that measure a person’s 
immune reactivity to M. tuberculosis. The QFT-G was 
approved by the Food and Drug Administration in 2005. 
The QFT-G is used to help diagnose M. tuberculosis 
infection in persons suspected of having either LTBI or 
TB disease. The QuantiFERON®-TB Gold In-Tube 
was approved by the Food and Drug Administration in 
October 2007; however, CDC guidelines for use in 
determining TB infection are currently being established. 
Conducting a QFT-G 
To conduct a QFT-G, first read the instructions from the 
manufacturer and then follow the steps below:
	 Confirm arrangements for delivery and testing of 
blood in a qualified laboratory within 12 hours of 
blood sample collection.  
	 Draw a sample of whole blood from the patient 
into a tube with heparin, according to 
manufacturer’s instructions. 
	 Schedule an appointment for the patient to receive
test results and, if then needed, medical evaluation 
and possible treatment for LTBI or TB disease. 
Before conducting a QFT-G, arrangements should be 
made with a laboratory qualified for processing blood for 
a QFT-G analysis. Next a sample of whole blood should 
be drawn from a patient into a tube with heparin, an anti­
clotting agent. The patient’s blood samples must then be 
delivered to the laboratory within 12 hours for analysis. 
An appointment should be scheduled with the patient to 
discuss test results, and if needed, medical evaluation and 
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. . . . . . . . . . . . . . . . . . . . . . . 
Patient’s blood samples are
mixed with antigens found in 
M. tuberculosis strains.
. . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . 
QFT-G results are based on 
the amount of IFN-γ released 
in response to the antigens 
and control substances. 
. . . . . . . . . . . . . . . . . . . . . . . 
How a QFT-G Works  
At the laboratory, the patient’s blood samples are mixed 
with antigens (protein substances that can produce an 
immune response) and incubated for 16 to 24 hours. The 
antigens used, ESAT-6 and CFP-10, are found in 
M. tuberculosis strains. If a person is infected with 
M. tuberculosis, the blood cells in the sample will 
recognize the antigens and release interferon-gamma 
(IFN-γ) in response. IFN-γ is a protein that is normally 
produced by the body in response to infections. 
Blood samples are also mixed with control substances, 
mitogen and saline. These controls are used for 
comparison purposes to help verify test results and to 
determine a person’s background level of IFN-γ. 
The QFT-G results are based on the amount of IFN-γ that 
is released in response to the M. tuberculosis antigens and 
control substances. As with the TST, medical evaluation 
and additional tests (such as chest x-rays, sputum smears, 
and culture) are needed to confirm the diagnosis of LTBI 
or TB disease. 
Interpreting QFT-G Results  
Interpretation of the QFT-G result is based on the IFN-γ
concentrations in the test samples. To help calculate the 
results, laboratories can use software provided by the 
manufacturer. The laboratory conducting the analysis of 
the QFT-G will then submit a report of the results back to 
the health care provider who requested the test.  
The laboratory report should include interpretation of 
QFT-G results and indicate the concentration of IFN-γ in 
each blood sample. The test results will be reported as 
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Report of QFT-G Results 
QFT-G Result Report/Interpretation 
Positive M. tuberculosis infection likely 
Negative M. tuberculosis infection unlikely, but cannot be 
excluded especially if 
1. Patient has TB signs and symptoms  
2. Patient has a high risk for developing TB disease 
once infected with M. tuberculosis 
Indeterminate Test did not provide useful information about the 
likelihood of M. tuberculosis infection. Options are to 
repeat QFT-G test or give a TST or do no additional 
testing 
. . . . . . . . . . . . . . . . . . . . . . . . 
Persons who test positive for 
TB infection should be 
evaluated for TB disease and, 
if disease is ruled out, they 
should be considered for 
LTBI treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
If the result is positive, then it is likely that the patient has 
M. tuberculosis infection. There is no reason to follow a 
positive QFT-G result with a TST. However, TB disease 
should be ruled out by medical evaluation before LTBI is 
diagnosed. 
If the result is negative, then the patient is unlikely to have 
M. tuberculosis infection and may not require further 
evaluation unless they have signs and symptoms of TB 
disease. Moreover, as with the TST, persons who have a 
negative test result can still have LTBI. 
If the result is indeterminate, that means that test could not 
be interpreted. The options then are to retest the patient
with the QFT-G again or a TST or do no additional testing. 
Each QFT-G result and its interpretation should be 
considered in conjunction with other epidemiologic, 
historical, physical, and diagnostic findings. Regardless of 
test results, if a patient has signs and symptoms of TB 
disease or if they are at high risk for developing TB 
disease, they should be further evaluated. 
As with the TST, negative QFT-G results for contacts to 
persons with infectious TB should be confirmed with a 
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. . . . . . . . . . . . . . . . . . . . . . . . 
QFT-G can be used in all 
circumstances in which the 
TST is currently used. 
However, caution should be 
used when testing in certain 
populations because of 
limited data.
. . . . . . . . . . . . . . . . . . . . . . . . 
QFT-G Recommendations 
QFT-G can be used in all circumstances in which the TST 
is currently used, including contact investigations, 
evaluation of recent immigrants who have had BCG 
vaccination, and TB testing of health care workers and 
others undergoing serial evaluation for M. tuberculosis. 
However, caution should be used when testing certain 
populations because of limited data in the use of QFT-G. 
Furthermore, as with the TST, testing programs using 
QFT-G should only be implemented if plans are also in 
place for the necessary follow-up medical evaluation (such 
as chest x-rays) and treatment for persons diagnosed with 
LTBI or TB disease. 
Advantages of Using QFT-G 
The QFT-G and the TST measure different components of 
a patient’s immune response to determine if he or she is 
infected with M. tuberculosis. Furthermore, both tests are 
conducted differently. The QFT-G is conducted with blood 
samples analyzed in a laboratory, where as the TST is 
conducted by injecting tuberculin intradermally in the 
patient’s forearm. There are advantages and limitations to 
using the QFT-G. Below are listed some advantages to 
using the QFT-G compared to using the TST (Table 3.5). 
	 Requires a single patient visit to conduct the test
	 Results can be available in 24 hours 
	 Does not cause the booster phenomenon which can 
happen with repeat TSTs 
	 Less likely to have incorrect reading of results 
compared to the TST  
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. . . . . . . . . . . . . . . . . . . . . . . 
The QFT-G results can be
available in 24 hours. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . 
The QFT-G does not cause 
the booster phenomenon. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . 
BCG vaccination does not 
affect QFT-G results. 
. . . . . . . . . . . . . . . . . . . . . . . . 
An advantage of using the QFT-G compared to the TST is 
that it only requires one patient visit to conduct the test and 
results can be available in 24 hours. The TST requires two 
visits by the patient to obtain test results. The patient must 
come for their first visit to receive the TST and then for a 
second visit, 48 to 72 hours later, to have their TST 
reaction read. 
Since the QFT-G is a blood test conducted in a laboratory 
the patient is not exposed to the antigens. Thus, unlike the 
TST, there is no booster phenomenon when using the QFT­
G. Since the QFT-G does not cause the booster 
phenomenon, there is no need to use two-step testing.  
Another advantage of using the QFT-G is that there is less 
chance of reader bias since it is a laboratory-based test. The 
TST requires that the health care worker place, measure, 
and interpret the test. Thus there is more of a chance of an 
incorrect reading of the results of the TST. 
The antigens used in QFT-G, ESAT-6 and CFP-10, are not 
found in the BCG vaccine strains. Therefore, previous 
vaccination with BCG will not cause false-positive results 
when using the QFT-G as compared to using a TST.  
Table 3.5 
Advantages of Using the QFT-G Compared to Using the TST 
QFT-G Result TST 
Requires 1 patient visit to conduct the 
test 
Requires 2 patient visits to conduct the 
test (3 to 4 visits if 2 step testing) 
Results can be available in 24 hours Results are available 48 to 72 hours 
later 
Does not cause booster phenomenon Can cause booster phenomenon 
Not as likely to have incorrect reading 
BCG vaccination does not cause false-
positive result 
More likely to have incorrect reading 
BCG vaccination can cause false-
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. . . . . . . . . . . . . . . . . . . . . . . . 
Since the QFT-G is a new test 
for diagnosing infection with 
M. tuberculosis, there is still 
limited laboratory and medical 
experience with using the test. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Disadvantages and Limitations 
Since the QFT-G is a new test for diagnosing infection with 
M. tuberculosis, there is still limited laboratory and medical 
experience with using the test. Following are some known 
disadvantages and limitations to using the QFT-G.
	 Blood samples must be processed within 12 hours 
after collection 
	 Errors in running and interpreting the test can 

decrease the accuracy of the QFT-G 

	 There are limited data on the use of QFT-G in 
children younger than 17 years of age, among persons 
recently exposed to M. tuberculosis, persons living 
with HIV/AIDS, persons on immunosuppressive 
therapy (including corticosteroids or TNF-α
antagonists), persons with certain blood disorders, 
cancers, diabetes, silicosis, or severe kidney disease. 
	 There are limited data on the use of QFT-G to 
determine who is at risk for developing TB disease  
A potential disadvantage to using the QFT-G is that samples 
must be processed within 12 hours after collecting the blood. 
If they are not processed in 12 hours, the accuracy of the test 
is decreased. The accuracy of the test can also be affected by 
laboratory errors in running and interpreting the test. 
Therefore, efforts should be made to ensure that blood 
specimens are properly collected and promptly transported to 
a laboratory qualified in analyzing a QFT-G. 
Since the QFT-G is a new test, there are currently limited 
data on the use of QFT-G in certain populations. These 
include children younger than 17 years of age, persons living 
with HIV/AIDS, or other medical conditions including 
certain blood disorders and cancers, diabetes, silicosis, severe 
kidney disease, and immunosuppressive therapy [for 
example, corticosteroids or TNF-α antagonists]. There are 
also limited data on using QFT-G on persons who have been 
recently exposed to TB (contacts) and other populations at 
high risk of LTBI. 
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Study Questions 3.20 – 3.23 
3.20 What are the steps for conducting a QFT-G?
3.21 How are the QFT-G results interpreted?
3.22 How should a negative QFT-G result be interpreted?
3.23 What are five advantages for using QFT-G as compared to the TST?
































Targeted Testing and the Diagnosis of 
Latent Tuberculosis Infection and Tuberculosis Disease 
Diagnosis of TB Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
Anyone with symptoms of TB 
or a positive TST or QFT-G 
result should be medically 
evaluated for TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The key to diagnosing TB is for clinicians to “think TB” 
when they see a patient with symptoms of the disease or 
abnormal chest x-ray findings. Because TB is not as 
common as it was many years ago in the United States, 
many clinicians do not consider the possibility of TB when 
making diagnoses for patients who have symptoms of TB. 
When this happens, the diagnosis of TB may be delayed or 
even overlooked, and the patient will remain ill and 
possibly infectious. 
Anyone with symptoms of TB or anyone found to have a 
positive TST or QFT-G result should be medically 
evaluated for TB disease. 
There are five components for conducting a complete 
medical evaluation for diagnosing TB disease.  
1. Medical history 
2. Physical examination 
3. Test for TB infection 
4. Chest x-ray
5. Bacteriological examinations  
1. The Medical History 
A medical history is the part of a patient’s life history that 
is important for diagnosing and treating the patient’s 
medical condition. It includes social, family, medical, and 
occupational information about the patient.  
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. . . . . . . . . . . . . . . . . . . . . . . . 
People with TB disease may 
or may not have symptoms. 
. . . . . . . . . . . . . . . . . . . . . . . . 
To obtain a medical history, the clinician should ask 

whether the patient has: 

a. Any symptoms of TB disease 
b.	 Been exposed to a person with infectious 
TB or has risk factors for exposure to TB 
c. Risk factors for developing TB disease 
d. Had LTBI or TB disease before 
Clinicians should suspect TB disease in patients with any 
of these factors. 
a. Symptoms of TB disease
People with TB disease may or may not have symptoms. 
However, most patients with TB disease have one or more 
symptoms that led them to seek medical care. 
Occasionally, TB is discovered during a medical 
examination for an unrelated condition (for example, when 
a patient is given a chest x-ray before undergoing surgery). 
Usually, when patients do have symptoms, the symptoms 
have developed gradually, and they have been present for 
weeks or even months. Pulmonary TB disease usually 
causes one or more of the following symptoms: 
 A cough (lasting for 3 or more weeks) 
 Chest pain when breathing or coughing 




 Night sweats 
 Weight loss
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. . . . . . . . . . . . . . . . . . . . . . . . 
The symptoms of
extrapulmonary TB disease 
depend on the part of the 
body that is affected by the 
disease. 
. . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . 
Some people may have been 
exposed to TB in the distant 
past, when they were 
children. Others may have 
been exposed more recently.  
. . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Some conditions appear to 
increase the risk that TB 
infection will progress to 
disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The symptoms of extrapulmonary TB disease depend on 
the part of the body that is affected by the disease. For 
example, TB of the spine may cause pain in the back; TB 
of the kidney may cause blood in the urine. 
All of these symptoms may be caused by other diseases, 
but they should prompt the clinician to suspect TB disease.
b. Exposure to TB 
Another important part of the medical history is asking the 
patient about his or her exposure to TB. Patients should be 
asked whether they have spent time with someone who has 
infectious TB. Some people may have been exposed to TB 
in the distant past, when they were children. Others may 
have been exposed more recently. 
Anyone who has been exposed to TB may have TB 
infection. Some people become infected with 
M. tuberculosis without knowing that they were exposed to 
it. The risk of being exposed to TB is higher for some
people. It is important to consider demographic factors (for 
example, country of origin, age, ethnic or racial group, or 
occupation) that may increase the patient’s risk for 
exposure to TB. For more details on groups at high risk for 
exposure to TB, see the Targeted Testing Section of this 
module, page 6. 
c. Risk factors for developing TB disease 
A third part of the medical history is checking for risk
factors for developing TB disease. Also, clinicians should 
see whether the patient has medical conditions, especially 
HIV infection, which can increase the risk of LTBI 
progressing to TB disease. All patients who do not know 
their current HIV status should be referred for HIV 
counseling and testing.
For more information on factors and medical conditions 
that can increase the risk of patients developing TB 
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. . . . . . . . . . . . . . . . . . . . . . . . 
The clinician should ask the 
patient whether he or she has 
ever been diagnosed with or 
treated for TB infection or 
disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
d. Previous TB infection or TB disease 
During the medical history, the clinician should ask the 
patient whether he or she has ever been diagnosed with or 
treated for TB infection or disease. 
	 Patients known to have a positive TST or QFT-G 
result probably have TB infection. If they were 
infected within the past 2 years, they are at high-risk 
for developing TB disease. 
	 Patients who have had TB disease before should be 
asked when they had the disease and how the disease 
was treated.  
Clinicians may also contact the local health department for 
information about whether a patient has received TB 
treatment in the past. If the treatment regimen that was 
prescribed was inadequate or if the patient did not follow the
recommended treatment, the TB disease may come back, 
and it may be resistant to one or more of the drugs used.
2. Physical Examination 
A physical examination is an essential part of the evaluation 
of any patient. It cannot confirm or rule out TB disease, but 
it can provide valuable information about the patient’s 
overall condition and factors that may affect how TB 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Patients with symptoms of TB 
disease should always be 
evaluated for TB disease, 
regardless of their skin test 
results. 
. . . . . . . . . . . . . . . . . . . . . . . . 
3. Testing for TB Infection 
Currently, there are two tests available for diagnosing TB 
infection in the U.S.  
 Mantoux tuberculin skin test (TST) 
 QuantiFERON®-TB Gold test (QFT-G) 
Patients with symptoms of TB disease are sometimes given 
a TST or QFT-G to detect infection with TB. However, 
some patients with TB disease may have a negative TST or 
QFT-G result. Patients with symptoms should always be 
evaluated for TB disease, regardless of their TST or 
QFT-G results. Furthermore, for patients with symptoms of 
TB disease, clinicians should not wait for TST or QFT-G 
results before starting other diagnostic tests. Instead, the 
patient should be given a TST or QFT-G at the same time as 
the other steps in the diagnosis of TB disease. 
For more information on testing for TB infection, see 
Diagnosis of LTBI section of this module, page 8.
Study Questions 3.24 
3.24 	 What are the five components for conducting a medical evaluation for diagnosing 
TB disease? 
Answers to study questions are on pages 71 – 77. 
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Study Questions 3.25 – 3.27 
3.25 	 What parts of a patient’s medical history should lead a clinician to suspect TB?
3.26 	 What are the symptoms of pulmonary TB disease? What are the symptoms of 
extrapulmonary TB disease (pulmonary or extrapulmonary)?
3.27 	 For patients with symptoms of TB disease, should clinicians wait for TST or 
QFT-G results before starting other diagnostic tests?
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. . . . . . . . . . . . . . . . . . . . . . . . 
Chest x-rays are useful for 
diagnosing TB disease 
because pulmonary TB is  
the most common form of  
the disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
4. The Chest X-Ray 
The chest x-ray is useful for diagnosing TB disease 
because pulmonary TB is the most common form of the 
disease. Usually, when a person has TB disease in the 
lungs, the chest x-ray appears abnormal (Figure 3.6). It 
may show infiltrates (collections of fluid and cells in the 
tissues of the lung) or cavities (hollow spaces within the 
lung that may contain many tubercle bacilli).
 Figure 3.6 Abnormal chest x-ray. 
Arrow points to cavity in patient’s 
right upper lobe. Left lung is normal. 
The purposes of the chest x-ray are to 
	 Help rule out the possibility of pulmonary TB 
disease in a person who has a positive TST or a 
QFT-G result 
	 Check for lung abnormalities in people who have 
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. . . . . . . . . . . . . . . . . . . . . . . . 
The results of a chest x-ray 
cannot confirm that a person 
has TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
In HIV-infected patients, 
pulmonary TB may have an 
unusual appearance on the 
chest x-ray. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The results of a chest x-ray, however, cannot confirm that 
a person has TB disease. A variety of illnesses may 
produce abnormalities whose appearance on a chest x-ray 
resembles TB. Although an abnormality on a chest x-ray 
may lead a clinician to suspect TB, only a bacteriologic 
culture that is positive for M. tuberculosis proves that a 
patient has TB disease. Moreover, a chest x-ray cannot 
detect TB infection. 
In persons living with HIV, pulmonary TB disease may 
have an unusual appearance on the chest x-ray. The chest 
x-ray may even appear entirely normal. 
A chest x-ray may be used to rule out the possibility of 
pulmonary TB in a person who has had a positive TST 
result and no symptoms of disease. 
Study Questions 3.28 – 3.29 
3.28 	 Name two purposes of the chest x-ray. 
3.29 	 Can the results of a chest x-ray confirm that a person has TB disease? Why or 
why not?
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. . . . . . . . . . . . . . . . . . . . . . . . 
A bacteriologic examination 
is done in a laboratory that 
specifically deals with 
M. tuberculosis and other 
mycobacteria. 
. . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Patients suspected of having 
pulmonary TB disease may 
cough up sputum, which is 
collected in a sterile 
container for processing 
and examination. 
. . . . . . . . . . . . . . . . . . . . . . . . 
5. The Bacteriologic Examination 
Clinical specimens (for example, sputum or urine) are 
examined and cultured (grown) in the laboratory for the
bacteriologic examination. TB bacteriologic examination 
is done in a laboratory that specifically deals with 
M. tuberculosis and other mycobacteria (a 
mycobacteriology laboratory). The bacteriologic 
examination has five parts: 
a. Specimen collection 
b. 	 Examination of the acid-fast bacilli smears 




d. 	 Specimen culturing and identification 
e.	 Drug susceptibility testing 
a. 	Specimen collection
Specimens that will be sent to the laboratory can be 
obtained in several ways. Usually, patients who are 
suspected of having pulmonary TB disease simply cough 
up sputum (phlegm from deep in the lungs) into a sterile 
container for processing and examination (Figure 3.7). This 
is the least expensive and easiest procedure. A health care 
worker should coach and directly supervise the patient
when sputum is collected. Patients who are not supervised 
are not always successful in providing an adequate 
specimen, especially in their first attempt. 
Figure 3.7 A TB patient has coughed up sputum and is spitting it into a sterile container. The 
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. . . . . . . . . . . . . . . . . . . . . . . . 
For an induced sputum
sample, the patient inhales a 
saline mist, causing him or 
her to cough deeply. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
A bronchoscopy is done to 
obtain pulmonary secretions 
or lung tissue. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
For gastric washing, a tube is 
inserted through the patient’s 
nose and passed into the 
stomach to collect a sample 
of sputum that has been 
coughed into the throat and 
then swallowed. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Patients should have at least three sputum specimens 
examined. It is best to try and get the specimens early in 
the morning. If a patient cannot cough up sputum on his or 
her own, other techniques can be used to obtain a 
specimen. An induced sputum sample can be obtained by 
having the patient inhale a saline (salt water) mist, which 
causes the patient to cough deeply. This procedure is easily 
done, and it should be used to help patients cough up 
sputum if they cannot do so on their own. Induced 
specimens are often clear and watery; they should be 
labeled “induced specimen” so that they will not be 
confused with saliva. Laboratories will not accept saliva as 
a specimen. 
Another procedure, bronchoscopy, can be used to obtain 
pulmonary secretions or lung tissue. In this procedure, an 
instrument called the bronchoscope is passed through the 
mouth directly into the diseased portion of the lung, and 
some sputum or lung tissue is removed. Bronchoscopy 
should be used only when patients cannot cough up sputum
on their own and an induced specimen cannot be obtained. 
A fourth procedure, gastric washing, involves inserting a 
tube through the patient’s nose and passing it into the 
stomach. The idea is to get a sample of gastric secretions 
that contains sputum that has been coughed into the throat 
and then swallowed. Gastric washings are done in the 
morning because patients usually swallow sputum during 
the night. This procedure is usually used only when 
patients cannot cough up sputum on their own, an induced 
specimen cannot be obtained, and bronchoscopy cannot be 
done. However, gastric washings are often used for 
obtaining samples from children. Most children produce 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Health care workers should 
use precautions to control the 
spread of tubercle bacilli 
during sputum collection 
procedures. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
In patients with 
extrapulmonary TB disease, 
specimens are obtained in 
various ways, depending on 
the part of the body that is 
affected. 
. . . . . . . . . . . . . . . . . . . . . . . . 
It is very important for health care workers to use infection 
control precautions to control the spread of tubercle bacilli 
during these procedures and any other procedures that may 
cause persons who have pulmonary TB disease to cough. 
This is discussed further in Module 5, Infectiousness and 
Infection Control. 
In patients who have extrapulmonary TB disease, 
specimens other than sputum may be obtained. The 
specimen obtained from these patients depends on the part 
of the body that is affected. For example, urine samples are 
obtained from patients suspected of having TB disease of 
the kidney, and fluid samples are obtained from the area 
around the spine in patients suspected of having TB 
meningitis (TB disease in the membranes surrounding the 
brain and spinal cord). 
The methods of obtaining a sputum specimen are 
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Methods of Obtaining a Sputum Specimen  
Method Description Advantage Disadvantage 
Coughing up Patient coughs up Inexpensive Patient may not be able to 
sputum sputum
Easy to do 
cough up sputum on his 
or her own, or may spit up 
saliva instead of sputum 
Inducing sputum Patient inhales a 
saline mist, causing 
him or her to cough 
deeply 
Easy to do Specimens may be watery 
and may be confused with 




Bronchoscopy Bronchoscope is 
passed through the 
mouth or nose 
directly into the 
diseased portion of 
the lung, and some






sputum does not 
work 




Must be done by a 
specialized physician in a 
hospital or clinic 
Gastric washing Tube is inserted 
through the patient’s 
nose and passed into 
the stomach to get a 
sample of gastric 
secretions that contain
sputum that has been 
coughed into the 







little or no 
sputum when 
they cough 
Must be done as soon as 
patient wakes up in the 
morning; patient may be
required to stay in 
hospital 
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Case Study 3.5 
Mr. Lee has a cough and other symptoms of TB disease, and he is evaluated with 
a chest x-ray. However, he is unable to cough up any sputum on his own for the 
bacteriologic examination. 
 What should be done? 
Answers to case study questions are on pages 78 – 81. 
52
 
Targeted Testing and the Diagnosis of 














. . . . . . . . . . . . . . . . . . . . . . . . 
Specimens are smeared onto 
a glass slide and stained so 
that they can be examined for 
acid-fast bacilli (AFB) under 
a microscope. 
. . . . . . . . . . . . . . . . . . . . . . . . 
b. Examination of AFB smears 
Before the specimen is examined under a microscope, it is 
smeared onto a glass slide and stained with a dye. This is 
called a smear. Then laboratory personnel use the 
microscope to look for acid-fast bacilli (AFB) on the 
smear (Figure 3.8). AFB are mycobacteria that stay stained 
even after they have been washed in an acid solution. 
Tubercle bacilli are one kind of AFB. 
Figure 3.8 AFB smear. In this photograph, the AFB (shown in red) are tubercle bacilli. 
. . . . . . . . . . . . . . . . . . . . . . . . 
When AFB are seen in a 
smear, they are counted and 
classified according to the 
number of AFB seen. 
. . . . . . . . . . . . . . . . . . . . . . . . 
When AFB are seen in a smear, they are counted. There is 
a system for reporting the number of AFB that are seen at a 
certain magnification. According to the number of AFB 
seen, the smears are classified as 4+, 3+, 2+, or 1+. In 
smears classified as 4+, 10 times as many AFB were seen 
as in smears classified as 3+; in 3+ smears, 10 times as 
many as in 2+ smears; and in 2+ smears, 10 times as many 
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. . . . . . . . . . . . . . . . . . . . . . . . 
A negative smear does not 
rule out the possibility of TB 
because there can be AFB in 
the smear that were not seen. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The results of the smear 
examination can be used to 
help determine the 
infectiousness of the patient. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Smears that are classified as 4+ and 3+ are considered 
strongly positive; 2+ and 1+ smears are considered 
moderately positive. If very few AFB are seen, the smear is 
classified by the actual number of AFB seen (no plus sign). 
For example, if only 2 AFB were seen in the entire smear, 
the smear is classified as “2 AFB seen.” Smears classified 
in this way are considered weakly positive. Finally, if no 
AFB are seen, the smear is called negative. But a negative 
smear does not rule out the possibility of TB because 
there can be AFB in the smear that were not seen.
It takes only a few hours to prepare and examine a smear. 
Therefore, the results of the smear examination should be 
available to the clinician within 1 day. 
The results of the smear examination can be used to help 
determine the infectiousness (contagiousness) of the 
patient. Patients who have many tubercle bacilli in their 
sputum have a positive smear. Patients who have positive 
smears are considered infectious because they can cough 
many tubercle bacilli into the air. (This is discussed in more 
detail in Module 5, Infectiousness and Infection Control.) 
However, because AFB are not always tubercle bacilli, 
patients who have positive smears do not necessarily have 
TB. Furthermore, as mentioned previously, patients who 
have negative smears may have TB. 
Laboratories should report initial positive smears and 
positive M. tuberculosis cultures within 24 hours of 
specimen receipt by telephone or fax to the primary health 
care provider. Out-of-state laboratories who receive 
referral specimens must contact the health care provider in 
the patient’s state of origin. Follow-up results may be 
reported by mail. It is the responsibility of the primary 
health care provider to promptly report all suspected or 
confirmed cases of TB to the state or local health 
department. This will ensure that a contact investigation 
can be initiated quickly to interrupt the potential ongoing 
transmission. 
The classification of smears is summarized in Table 3.7. 
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Smear Classifications and Results 
Classification of Smear Smear Result Infectiousness of Patient 
4+ Strongly positive Probably very infectious
3+ Strongly positive Probably very infectious
2+ Moderately positive Probably infectious 
1+ Moderately positive Probably infectious 
Actual number of AFB seen 
(no plus sign) 
Weakly positive Probably infectious 
No AFB seen Negative May not be infectious* 
* The criteria for determining whether a patient may be considered noninfectious are discussed in Module 5,
Infectiousness and Infection Control.
Study Questions 3.30 – 3.32 
3.30 	 What are the four ways to collect sputum specimens? Indicate which procedure is the 
least expensive and easiest to perform. 
3.31 What do laboratory personnel look for in a smear?
3.32 What does a positive smear indicate about a patient’s infectiousness? 
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Case Study 3.6 
Ms. Thompson gave three sputum specimens, which were sent to the laboratory 
for smear examination and culture. The smear results were reported as 4+, 3+, 
and 4+. 
 What do these results tell you about Ms. Thompson’s diagnosis and her 
infectiousness? 
Answers to case study questions are on pages 78 – 81. 
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Case Study 3.7 
Mr. Sagoo has symptoms of TB disease and a cavity on his chest x-ray, but all of 
his sputum smears are negative for acid-fast bacilli.  
 Does this rule out the diagnosis of pulmonary TB disease? 
 Why or why not? 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Nucleic acid amplification 
test can be used to identify
M. tuberculosis from sputum
specimens. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
NAA test results can help 
guide clinicians decisions for 
patient therapy and isolation; 
however, they do not replace 
the need for AFB smear, 
culture, or clinical judgment. 
.. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
All specimens should be 
cultured, regardless of 
whether the smear is positive 
or negative. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Culturing the specimen is 
necessary to determine if it 
contains M. tuberculosis and 
to confirm a diagnosis of TB 
disease. 
. . . . . . . . . . . . . . . . . . . . . . . .
c. Direct identification of the specimen (nucleic acid 
amplification) 
Nucleic acid amplification (NAA) tests can be used for 
directly identifying M. tuberculosis from sputum
specimens. NAA tests, including polymerase chain 
reaction (PCR) and other methods, are used to amplify 
(copy) DNA and RNA segments, in to order to rapidly 
identify the microorganisms in the specimen.  
A patient can be presumed to have TB if they have a 
positive NAA test with an AFB positive smear. If a patient 
has a negative NAA test with an AFB positive smear, the 
patient may have a nontuberculous mycobacteria infection. 
NAA test results can help guide clinicians decisions for 
patient therapy and isolation; however, they do not replace 
the need for AFB smear, culture, or clinical judgment.  
Decisions about when and how to use NAA tests for TB 
diagnosis should be based on each individual situation. 
Laboratories should not reserve specimens for NAA tests if 
it will compromise the ability to perform the other 
diagnostic tests. 
d. Culturing and identifying the specimen
Culturing the specimen means growing the mycobacteria 
on solid media and in liquid media, substances that contain 
nutrients, in the laboratory (Figure 3.9). When the 
mycobacteria have formed colonies (groups), or when 
there is sufficient growth in the liquid media, they can be 
identified. All specimens should be cultured, regardless of 
whether the smear is positive or negative. 
Culturing the specimen is necessary to determine if it 
contains M. tuberculosis and to confirm a diagnosis of 
TB disease. However, in some cases, patients are 
diagnosed with TB disease on the basis of their clinical 
presentation (i.e., signs and symptoms), even if their 
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. . . . . . . . . . . . . . . . . . . . . . . . 
The first procedure in 
culturing the specimen is to 
detect the growth of the 
mycobacteria. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The second procedure is to 
identify the organism that has 
grown. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
A positive culture for  
M. tuberculosis confirms the 
diagnosis of TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The first procedure in culturing the specimen is to detect 
the growth of the mycobacteria. Mycobacteria grow very 
slowly. When solid media are used to culture the specimen, 
it can take as long as 3 to 6 weeks for the growth of the 
mycobacteria to be detected. However, rapid culturing 
methods that involve liquid media can decrease this time to 
4 to 14 days. 
The second procedure is to identify the organism that has 
grown in the culture. All types of mycobacteria will grow 
in solid or liquid media. For this reason, laboratory tests 
must be done to determine whether the organism is 
M. tuberculosis or one of the nontuberculous mycobacteria. 
Nucleic acid probes can rapidly identify the type of 
mycobacteria present in the specimens in 2 to 4 hours. 
Thus, using liquid media and nucleic acid probes, it is 
usually possible to culture and to identify M .tuberculosis 
within two weeks. 
If traditional solid medium and biochemical tests are used 
for both the isolation and identification of the organism, the 
entire process can take 6 to 12 weeks. 
When M. tuberculosis is identified in a patient’s culture, 
the patient is said to have a positive culture for 
M. tuberculosis. A positive culture for M. tuberculosis, also 
called a M. tuberculosis isolate, confirms the diagnosis of 
TB disease.
When M. tuberculosis is NOT identified in a patient’s 
culture, the patient is said to have a negative culture for 
M. tuberculosis. A negative culture does not necessarily 
rule out the diagnosis of TB disease; as mentioned earlier, 
some patients with negative cultures are diagnosed with TB 
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Follow-up bacteriological examinations are important for 
assessing the patients infectiousness and response to 
treatment. Specimens should be obtained monthly until 2 
consecutive specimen cultures are negative. Culture 
conversion is the most important objective measure of 
response to treatment. 
The differences between sputum smears and cultures are 
summarized in Table 3.8. 
Table 3.8 
Differences Between Sputum Smears and Cultures 
Feature Smears (see Figure 3.8) 
Cultures 
(see Figure 3.9) 
Equipment needed Microscope, glass slides, 
special dyes 
Incubators, safety cabinet, 
culture plates or tubes, culture 
media, biochemicals for tests 
Time needed to make report 1 day 4 days to 12 weeks (depending 
on method used) 
Basis of procedure Looking for AFB on slide 
under microscope 
Growth and identification of 
tubercle bacilli or other 
mycobacteria on culture media 
in incubator
Significance of a negative 
report 
Patient is less likely to be 
infectious 
Does not rule out TB disease 
(culture may be positive) 
No live tubercle bacilli found 
in the specimen  
Does not rule out TB disease 
(live tubercle bacilli may be in 
other specimens and/or in the 
patient) 
Significance of a positive 
report 
Patient is more likely to be 
infectious (if AFB are tubercle 
bacilli) 
AFB could be nontuberculous 
mycobacteria 
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Criteria for Reporting TB Cases
All 50 states, the District of Columbia, New York City, Puerto Rico, and seven 
other jurisdictions in the Pacific and the Caribbean report TB cases to the federal 
Centers for Disease Control and Prevention (CDC) using a standard case report 
form called the Report of Verified of Case of Tuberculosis (RVCT). Each reported 
TB case is checked to make sure that it meets certain criteria. All cases that meet 
the criteria, called verified TB cases, are counted each year. 
Cases that meet one of these four sets of criteria are counted as verified TB cases: 
1. The patient has a positive culture for M. tuberculosis
or 
2. The patient has a positive NAA test for M. tuberculosis*
or 
3. The patient has a positive smear for AFB, but a culture has not been done or 
cannot be done 
or 
4. If in the absence of laboratory confirmation, the patient has a positive TST 
reaction, has other signs and symptoms of TB disease, is being treated with 
two or more TB drugs, and has been given a complete diagnostic evaluation  
In addition, cases that do not meet any of these sets of criteria (for example, a 
patient who is anergic and has a negative culture for M. tuberculosis but who 
has signs and symptoms of TB disease) may be counted as a verified TB case if 
a health care provider has reported the case and decided to treat the patient 
for TB disease. 
*Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species. However,
for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug 
Administration (FDA) and used according to the approved product labeling on the package insert. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Drug susceptibility tests 
should be done when a 
patient is first found to have a 
positive culture for 
M. tuberculosis.
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Drug susceptibility tests 
determine which drugs will 
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are causing disease in a 
particular patient. 
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The results of drug 
susceptibility tests can help 
clinicians choose the 
appropriate drugs for each 
patient. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Drug susceptibility tests 
should be repeated if a 
patient has a positive culture 
for M. tuberculosis after 3 
months of treatment or if a 
patient does not seem to be 
getting better. 
. . . . . . . . . . . . . . . . . . . . . . . .
e. Drug susceptibility testing 
For all patients, drug susceptibility tests should be done 
when the patient is first found to have a positive culture for 
M. tuberculosis (that is, the first isolate of M. tuberculosis). 
Drug susceptibility tests are done to determine which drugs 
will kill the tubercle bacilli that are causing disease in a 
particular patient. Tubercle bacilli that are killed by a 
particular drug are said to be susceptible to that drug, 
whereas those that can grow even in the presence of a 
particular drug are said to be resistant to that drug. The 
drug susceptibility pattern of a strain of tubercle bacilli is 
the list of drugs to which the strain is susceptible and to 
which it is resistant.  
Drug-resistant TB can be mono-resistant if the tubercule 
bacilli are resistant to any one TB treatment drug, or poly-
resistant if resistant to at least two TB drugs (but not both 
isoniazid and rifampin). A patient is diagnosed with 
multidrug-resistant TB (MDR TB) if the tubercle bacilli 
are resistant to at least isoniazid and rifampin, the two best 
first-line TB treatment drugs. A patient is diagnosed with 
extensively drug-resistant TB (XDR TB) if the tubercle 
bacilli are resistant to isoniazid and rifampin, plus resistant 
to any fluoroquinolone and at least one of three injectable 
second-line drugs (such as amikacin, kanamycin, or 
capreomycin). 
The results of drug susceptibility tests can help clinicians 
choose the appropriate drugs for treating each patient. This 
is very important. Patients with TB disease who are treated 
with drugs to which their strain of TB is resistant may not 
be cured. In fact, their strain of TB may become resistant to 
additional drugs. 
Drug susceptibility tests should be repeated if a patient has 
a positive culture for M. tuberculosis after 3 months of 
treatment or if a patient does not seem to be getting better. 
That way, the clinician can find out whether the patient’s 
strain of TB has become resistant to certain drugs; if 
necessary, the clinician may change the drugs used for 
treating the patient.  Clinicians treating patients with drug-
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who is familiar with the treatment of drug-resistant TB. 
In the laboratory, drug susceptibility testing can be done 
using a liquid medium or a solid medium method. In a drug 
susceptibility test, organisms that grow in media containing 
a specific drug are considered resistant to that drug (Figure 
3.10). Liquid medium methods are faster than solid media 
methods for determining susceptibility to first-line TB 
medications. Usually the susceptibility results can be 
obtained within 7 to 14 days with the liquid medium 
method. Traditional solid medium methods, can take as 
long as 21 days. 
Figure 3.10 Drug susceptibility testing on solid media. Organisms are resistant to the drug in 
the upper right compartment and susceptible to the drugs in the lower compartments. Upper left 
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Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 3.33 – 3.36 
3.33 	 Why is it necessary to culture a specimen?
3.34 	 What does a positive culture for M. tuberculosis mean? How is this important for 
the TB diagnosis?
3.35 	 Why are drug susceptibility tests done?
3.36 	 How often should drug susceptibility tests be done?
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Case Study 3.8 
In the public health clinic, you see a patient, Ms. Sanchez, who complains of 
weight loss, fever, and a cough of 4 weeks’ duration. When questioned, she reports 
that she has been treated for TB disease in the past and that she occasionally 
injects heroin. 
 What parts of Ms. Sanchez’s medical history lead you to suspect TB 
disease? 
 What diagnostic tests should be done? 
Answers to case study questions are on pages 78 – 81. 
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SUMMARY
Targeted testing for TB infection is done to identify persons who are at high risk of developing 
TB disease and who would benefit from LTBI treatment. All testing activities should be 
accompanied by a plan for follow-up care, medical evaluation, and treatment for persons with 
latent TB infection or TB disease. Persons with a positive test for TB infection should be 
evaluated for TB disease and, if disease is ruled out, considered for treatment for LTBI.  
Flexibility is needed in defining high-risk groups for testing. High-risk groups can be divided 
into two categories:
 People at high risk for TB exposure or infection with M. tuberculosis
 People at high risk for developing TB disease once infected with M. tuberculosis
Currently, the available methods for detecting M. tuberculosis infection are the TST and 
interferon-gamma release assays (IGRA) such as the QFT-G. The TST and the QFT-G measure 
different components of the immune response and are administered differently.  
The TST is more commonly used and is done by using a needle and syringe to inject tuberculin 
between the layers of the skin, usually on the forearm. After 48 to 72 hours, the patient’s arm is 
examined for a reaction (an induration). The diameter of the indurated area (the swelling, not the 
redness) is measured across the forearm. Most people with TB infection have a positive reaction 
to the tuberculin. The interpretation of the TST depends on the size of the induration, the 
person’s risk factors for TB, and for people who may be exposed to TB on the job, the risk of 
exposure to TB in the person’s job. 
Several factors can affect how the TST reaction is interpreted. Some factors, such as infection 
with non-tuberculosis mycobacteria (NTM) and vaccination with BCG, can cause false-positive 
reactions. Other factors, such as anergy, recent infection, very young age, and recent live virus 
vaccination can cause false-negative reactions. Incorrect methods for giving and interpreting the 
TST can lead to either a false-positive or false-negative reaction.  
In many TB testing programs, two-step testing is used for skin testing employees when they start 
their job. Two-step testing is a strategy for telling the difference between boosted reactions and 
reactions caused by recent infection. 
The QFT-G is a FDA approved interferon-gamma release assay.  It is a blood test for TB 
infection. The patient’s blood samples must be delivered to a qualified laboratory within 12 
hours of collecting the samples. 
At the laboratory, the blood samples are mixed and incubated with antigens found in 
M. tuberculosis strains and with control substances. The results of the QFT-G depend upon the 
amount of IFN-γ released in response to the antigens and the control substances. The laboratory 
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The QFT-G can be used in all circumstances in which the TST is currently used. However, there 
are both advantages and limitations for using the QFT-G. Advantages include that the QFT-G 
requires only one patient visit to conduct the test and that the results are available in 24 hours. 
Also, unlike the TST, the QFT-G does not cause the booster phenomenon and results are not 
affected by BCG vaccination. Furthermore, since the QFT-G is a laboratory-based test, there is 
less chance of having an incorrect reading of the results as compared to the TST. 
There are some disadvantages and limitations for using the QFT-G. For a QFT-G, blood samples 
must be processed within 12 hours at a qualified laboratory. Thus efforts must be made to ensure 
that the specimens are promptly delivered to a qualified laboratory. Also, since the QFT-G is a 
new test, there are currently limited data on the use of it in certain populations. These include 
children younger than 17 years of age and persons living with HIV/AIDs and other medical 
conditions. There is also limited data on using QFT-G on persons who have been recently 
exposed to TB (contacts) and other populations at high risk for LTBI.  
Regardless of the testing method used (TST or QFT-G), patients with positive results should be 
evaluated for TB disease. If TB disease is ruled-out, the patient should be considered for LTBI 
treatment. Furthermore, recent contacts of someone with infectious TB disease who have a 
negative TST or QFT-G result should be retested 8 to 10 weeks after the last time they were in 
contact with the person who has TB. 
There are five components for conducting a complete medical evaluation for diagnosing TB 
disease. The first is the medical history. This means checking if the person has symptoms of TB 
disease; has been exposed to a person with TB or has other exposure risk factors; has had TB 
infection or TB disease before; or has risk factors for developing TB disease. The symptoms of 
pulmonary TB disease include coughing lasting for 3 or more weeks, pain in the chest when 
breathing or coughing, and coughing up sputum or blood. The general symptoms of TB disease 
(pulmonary or extrapulmonary) include weight loss, fatigue, malaise, fever, and night sweats. 
Other symptoms of extrapulmonary TB disease depend on the part of the body that is affected by 
the disease.  
The second component of the medical evaluation is the physical examination. Patients should be 
given a physical examination to determine their overall condition and factors that may affect how 
TB disease is treated if it is diagnosed. 
For the third component of the medical evaluation, patients with symptoms of TB disease may be 
given a TST or a QFT-G to help confirm infection with M. tuberculosis. However, patients 
should always be evaluated for TB disease, regardless of their TST or QFT-G results.  
The fourth component of the medical evaluation is the chest x-ray. A chest x-ray helps rule out 
the possibility of pulmonary TB disease in a person who has a positive result to the TST or QFT­
G. Chest x-rays also help determine if there are lung abnormalities in people who have 
symptoms of TB disease. However, chest x-ray results cannot confirm that a person has TB 
disease. Furthermore, chest x-rays for people living with HIV and pulmonary TB may appear 
unusual or even normal. 
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The fifth component of the medical evaluation is the bacteriologic examination. First, a sputum
specimen is obtained from patients suspected of having pulmonary TB disease; other specimens 
are obtained from patients suspected of having extrapulmonary TB disease. The specimen is 
smeared onto a slide, stained, and examined under a microscope for the presence of acid-fast 
bacilli. When acid-fast bacilli are seen in a smear, they are counted, and the smear is classified 
according to this number. Patients with positive smears are considered infectious.  
Next, based on clinical and laboratory decision, nucleic acid amplification (NAA) tests can be 
used on the sputum specimen to help identify the microorganisms. NAA test results can help 
guide clinicians decisions for patient therapy and isolation; however, they do not replace the 
need for AFB smear, culture, or clinical judgment.  
The specimen is then cultured, or grown, so that laboratory personnel can determine whether it 
contains M. tuberculosis. Special tests are used to identify the mycobacteria once they have 
grown enough to be detected. A positive culture for M. tuberculosis confirms the diagnosis of 
TB disease.
Finally, the cultured specimen is also tested for drug susceptibility. The results of drug 
susceptibility tests can help clinicians choose the appropriate drugs for each patient and 
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ANSWERS TO STUDY QUESTIONS 
3.1.	 What is the TST used for?  (page 8) 
The TST is used to determine whether a person has TB infection. 
3.2.	 How is the Mantoux TST given?  (page 8) 
The Mantoux TST is given by using a needle and syringe to inject 0.1 ml of 5 tuberculin 
units of liquid tuberculin between the layers of the skin (intradermally), usually on the 
forearm.
3.3.	 With the TST, when is the patient’s arm examined?  (page 9) 
The patient’s arm is examined 48 to 72 hours after the tuberculin is injected. 
3.4.	 How is the induration measured?  (pages 9-10) 
The diameter of the indurated area is measured across the forearm; erythema (redness) 
around the indurated area is not measured, because the presence of erythema does not 
indicate that a person has TB infection. 
3.5.	 Why is the Mantoux TST preferable to multiple-puncture tests?  (page 9) 
The Mantoux TST is preferable to multiple-puncture tests because it is more accurate. In 
multiple-puncture tests, the amount of tuberculin that actually enters the skin cannot be 
measured. In the Mantoux TST, however, the amount of tuberculin can always be 
measured. Therefore, the Mantoux TST is more accurate, and it is the preferred method. 
3.6.	 What two factors determine the interpretation of a TST reaction as positive or 
negative? What additional factor is considered for people who may be exposed to TB 
on the job? (pages 13-14) 
The two factors that are used to determine the interpretation of a TST include the size of 
the induration and the person’s risk factors for TB. 
For people who may be exposed to TB on the job, an additional factor is considered is the 
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3.7.	 For which groups of people is 5 or more millimeters of induration considered a 
positive reaction? Name four. (page 15) 
An induration of 5 or more millimeters is considered a positive reaction for  
 People living with HIV 
 Recent contacts of people with infectious TB 
 People who have had TB disease before 
 Patients with organ transplants and those taking a prolonged course of oral or 
intravenous corticosteroids or TNF-α
3.8.	 For which groups of people are 10 or more millimeters of induration considered a 
positive reaction? Name seven. (page 15) 
An induration of 10 or more millimeters is considered a positive reaction for  
 Recent arrivals to the United States (<5 years) from areas of the world where TB is 
common 
 People who inject illegal drugs 
 Mycobacteriology lab workers 
 People who live or work in high-risk congregate settings 
 People with certain medical conditions that place them at high risk for TB
 Children younger than 4 years 
 Infants, children and adolescents exposed to adults in high-risk categories 
3.9.	 For which group of people is 15 or more millimeters of induration considered a 
positive reaction? (page 15) 
An induration of 15 or more millimeters is considered a positive reaction for people with 
no risk factors for TB. 
3.10. Name four factors that can cause false-positive reactions to the TST.  (page 18) 
 Infection with nontuberculous mycobacteria (NTM) (mycobacteria other than 
M. tuberculosis)
 BCG vaccination 
 Administration on incorrect antigen 
 Incorrect measuring or interpretation of the TST reaction 
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3.11. Is there a reliable way to distinguish a positive TST reaction caused by vaccination 
with BCG from a reaction caused by true TB infection?  (page 18) 
No, there is no reliable way to distinguish a positive TST reaction caused by vaccination 
with BCG from a reaction caused by true TB infection. When using the TST, people who 
have been vaccinated with BCG should always be further evaluated for LTBI or TB 
disease the same as if they were not vaccinated with BCG.  
3.12. Name six factors that can cause false-negative reactions to the TST.  (page 21) 
False-negative reactions may be due to 
 Anergy 
 Recent TB infection (within the past 8- 10 weeks)
 Very young age (younger than 6 months ) 
 Recent live-virus measles or smallpox vaccination  
 Incorrect method of giving the TST  
 Incorrect measuring or interpretation of TST reaction 
3.13. What is anergy? (page 21) 
Anergy is the inability to react to skin tests because of a weakened immune system. Many 
conditions, such as HIV infection, cancer, or severe TB disease itself, can weaken the 
immune system and cause anergy. HIV infection is an important cause of anergy. 
3.14. After TB has been transmitted, how long does it take before TB infection can be 
detected by the TST? (page 22) 
After TB has been transmitted, it takes 2 to 8 weeks before TB infection can be detected 
by the TST. 
3.15. What should be done if a patient has a negative TST reaction but has symptoms of 
TB disease? (page 22) 
Any patient with symptoms of TB disease should be evaluated for TB disease, regardless 
of his or her skin test reaction. In fact, people with symptoms of TB disease should be 
evaluated for TB disease right away, at the same time that the TST is given.  
3.16. What is the booster phenomenon? (page 27) 
The booster phenomenon is a phenomenon in which people (especially older adults) who 
are skin tested many years after becoming infected with M. tuberculosis may have a 
negative reaction to an initial skin test, followed by a positive reaction to a skin test given 
up to a year later. This happens because in some people who have TB infection, the 
ability to react to tuberculin lessens over time. The first skin test “jogs the memory” of 
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3.17. What is the purpose of two-step testing?  (page 29) 
The purpose of two-step testing is to tell the difference between boosted reactions and 
reactions caused by recent infection. Because it provides accurate information about each 
employee’s baseline skin test reaction, two-step testing is used in many TB screening 
programs for skin testing employees when they start their job. 
3.18. In what type of situation is two-step testing used?  (page 29) 
Two-step testing is used in many TB screening programs for skin testing employees 
when they start their job.
3.19. How is two-step testing done?  (page 29) 
If a person has a negative reaction to an initial skin test, he or she is given a second test 1 
to 3 weeks later. 
 If the reaction to the second test is positive, it is considered a boosted reaction (due
to TB infection that occurred a long time ago). 
	 If the reaction to the second test is negative, the person is considered uninfected. In 
this person, a positive reaction to a TST given later on will probably be due to recent 
TB infection.
3.20. What are the steps for conducting a QFT-G? (page 33) 
To conduct a QFT-G, first read the instructions from the manufacturer and then follow 
the steps below:
 Confirm arrangements for delivery and testing of blood in a qualified laboratory 
within 12 hours of blood sample collection.  
	 Draw a sample of whole blood from the patient into a tube with heparin, according 
to manufacturer’s instructions. 
	 Schedule an appointment for the patient to receive test results and, if then needed, 
medical evaluation and possible treatment for LTBI or TB disease. 
3.21. How are the QFT-G results interpreted?  (page 34)  
Interpretation of the QFT-G result is based on the IFN-γ concentrations in the test 
samples. To help calculate the results, laboratories can use software provided by the 
manufacturer. A report of the results is submitted to the requesting clinician.  
3.22. How would a negative QFT-G result be interpreted  (page 35) 
If the result is negative, then the patient is unlikely to have M. tuberculosis infection and 
may not require further evaluation unless they have signs and symptoms of TB disease. 
Moreover, as with the TST, persons who have a negative test result can still have LTBI. 
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3.23. What are the five advantages for using QFT-G compared to the TST (page 36) 
 Requires a single patient visit to conduct the test
 Results can be available in 24 hours 
 Does not cause the booster phenomenon which can happen with repeat TSTs 
 Less likely to have incorrect reading of results compared to the TST  
 BCG vaccination does not affect QFT-G results 
3.24. What are the five components for conducting a complete medical evaluation for 
diagnosing TB disease? (page 40) 
 Medical history 
 Physical examination 
 Test for TB infection 
 Chest x-ray
 Bacteriologic examinations 
3.25. What parts of a patient’s medical history should lead a clinician to suspect TB?  
(page 41) 
Clinicians should suspect TB disease in patients who have 
 Symptoms of TB disease 
 Been exposed to a person who has infectious TB or has other risk factors for 
exposure to TB 
 Risk factors for developing TB disease 
 Had TB infection or TB disease before  
3.26. What are the symptoms of pulmonary TB disease? What are the symptoms of 
extrapulmonary TB disease? (pages 41-42) 
Pulmonary TB disease usually causes one or more of the following symptoms: 
 Coughing  Fatigue 
 Pain in the chest when breathing or  Malaise 
coughing 
 Fever 
 Coughing up sputum or blood 
 Night sweats 
 Weight loss 
The symptoms of extrapulmonary TB disease depend on the part of the body that is 
affected by the disease. For example, TB of the spine may cause pain in the back; TB of 
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3.27. For patients with symptoms of TB disease, should clinicians wait for TST or QFT-G 
results before starting other diagnostic tests?  (page 43) 
No. For patients with symptoms of TB disease, clinicians should not wait for TST or 
QFT-G results before starting other diagnostic tests. 
3.28. Name two purposes of the chest x-ray.  (page 46) 
The purposes of the chest x-ray are to 
 Help rule out the possibility of pulmonary TB disease in a person who has a positive 
TST or QFT-G result and no symptoms of TB 
 Check for lung abnormalities in people who have symptoms of TB disease 
3.29. Can the results of a chest x-ray confirm that a person has TB disease? Why or why 
not? (page 47) 
No, the results of a chest x-ray cannot confirm that a person has TB disease. This is 
because a variety of illnesses may produce abnormalities whose appearance on a chest x-
ray resembles TB. Although an abnormality on a chest x-ray may lead a clinician to 
suspect TB, only a bacteriologic culture that is positive for M. tuberculosis proves that a 
patient has TB disease. 
3.30. What are the four ways to collect sputum specimens? Indicate which procedure is the 
least expensive and easiest to perform. (pages 48-51) 
	 Usually, patients who are suspected of having pulmonary TB disease simply cough 
up sputum and the sputum is collected in a sterile container for processing and 
examination. This is the least expensive and easiest procedure. If a patient cannot 
cough up sputum on his or her own, other techniques can be used to obtain a 
specimen. 
	 An induced sputum sample can be obtained by having the patient inhale a saline (salt 
water) mist, which causes the patient to cough deeply.  
	 Bronchoscopy can be used to obtain pulmonary secretions or lung tissue. In this 
procedure, an instrument called the bronchoscope is passed through the nose or 
mouth directly into the diseased portion of the lung, and some sputum or lung tissue 
is removed.  
	 Gastric washing involves inserting a tube through the patient’s nose and passing it 
into the stomach. The idea is to get a sample of gastric secretions that contain 
sputum that has been coughed into the throat and then swallowed.  
3.31. What do laboratory personnel look for in a smear?  (page 53) 
Laboratory personnel use the microscope to look for acid-fast bacilli (AFB) on the smear. 
AFB are mycobacteria that stay stained even after they have been washed in an acid 
solution. Tubercle bacilli are one kind of AFB. 
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3.32. What does a positive smear indicate about a patient’s infectiousness?  (page 54) 
The results of the smear examination can be used to help determine the infectiousness 
(contagiousness) of the patient. Patients who have many tubercle bacilli in their sputum
have a positive smear. Patients who have positive smears are considered infectious 
because they can cough many tubercle bacilli into the air.  
3.33. Why is it necessary to culture a specimen? (page 58) 
Culturing the specimen is necessary to determine whether the specimen contains 
M. tuberculosis and to confirm a diagnosis of TB disease. (However, in some cases, 
patients are diagnosed with TB disease on the basis of their signs and symptoms, even if 
their specimen does not contain M. tuberculosis.)
3.34. What does a positive culture for M. tuberculosis mean? How is this important for the 
TB diagnosis?  (page 60) 
A positive culture for M. tuberculosis means that M. tuberculosis has been identified in a 
patient’s culture. A positive culture for M. tuberculosis confirms the diagnosis of TB 
disease. 
3.35. Why are drug susceptibility tests done?  (page 63) 
Drug susceptibility tests are done to determine which drugs will kill the tubercle bacilli 
that are causing disease in a particular patient. The results of drug susceptibility tests can 
help clinicians choose the appropriate drugs for each patient.  
3.36. How often should drug susceptibility tests be done?  (page 63) 
Drug susceptibility tests should be done when a patient is first found to have a positive 
culture for M. tuberculosis. In addition, drug susceptibility tests should be repeated if a 
patient has a positive culture for M. tuberculosis after 3 months of treatment or if a 
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ANSWERS TO CASE STUDIES 
3.1.    Which of the following patients have a positive TST reaction? 
a. 	 Mr. West, 36 years old, HIV infected, 8 mm of induration 
b. 	 Ms. Hernandez, 26 years old, native of Mexico, 7 mm of induration 
c. 	 Ms. Jones, 56 years old, has diabetes, 12 mm of induration 
d. 	 Mr. Sung, 79 years old, resident of a nursing home, 11 mm of induration 
e. 	 Mr. Williams, 21 years old, no known risk factors, 13 mm of induration 
f. 	 Ms. Marcos, 42 years old, chest x-ray findings suggestive of previous TB, 6 
mm of induration 
g. 	 Ms. Rayle, 50 years old, husband has pulmonary TB, 9 mm of induration 
(a, c, d, f, g) 
3.2.	 A 30-year-old man who recently immigrated from India is given a TST and found to 
have 14 millimeters of induration. He reports that he was vaccinated with BCG as a 
child. He also says that his wife was treated for pulmonary TB disease last year. 
	 How should this man’s results be interpreted? 
This man does have a positive reaction to the TST (10 or more millimeters is 
considered a positive reaction for a person from a country where TB is common). 
Also, he is a contact of person with pulmonary TB (his wife). However, because he 
was vaccinated with BCG there is a possibility that this may be a false-positive 
reaction. However, since there is no reliable way to distinguish a positive TST 
reaction caused by BCG or from a true TB infection, this man should be further 
evaluated for LTBI or TB disease as if he was not vaccinated with BCG. 
	 What factors make it more likely that this man’s positive reaction is due to TB 
infection? 
This man is from an area of the world where TB is common, so he was probably 
exposed to TB in his native country. Therefore, he is at increased risk for TB 
infection. Also, his wife has had pulmonary TB, which further increases the 
probability that he has been exposed to TB. Since there is no reliable way to 
distinguish a positive TST reaction caused by BCG from a true TB infection, this man 
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3.3.	 Mr. Bell comes to the TB clinic for a TST. He believes that he has been exposed to 
TB, and he knows he is at high risk for TB because he is HIV infected. He is given a 
TST, and his reaction is read 48 hours later as 0 millimeters of induration. 
	 What are three ways to interpret this result?
There are three possible reasons why Mr. Bell had no reaction to the tuberculin skin 
test. 
o	 First, he may not have TB infection.  
o	 Second, he may be anergic. People who are HIV infected are more likely to be 
anergic than persons who are not HIV infected. If Mr. Bell is anergic, he 
would be unable to react to tuberculin even if he did have TB infection.  
o	 Third, it may be less than 8 to 10 weeks since he was exposed to TB. After TB 
has been transmitted, it takes 2 to 8 weeks before TB infection can be detected 
by the tuberculin skin test. Mr. Bell should be retested 8 to 10 weeks after he 
was last exposed to TB. 
3.4.	 Ms. Wilson is a 60-year-old nurse. When she started a job at the local hospital, she 
was given a TST, her first test in 25 years. Her reaction was read 48 hours later as 0 
millimeters of induration. Six months later, she was retested as part of the TB 
screening program in the unit where she works. Her TST reaction was read 48 hours 
later as 11 millimeters of induration. 
	 What are two ways to interpret this result? 
There are two possible explanations for this result.  
o	 One explanation is that Ms. Wilson may have been exposed to and infected 
with M. tuberculosis sometime in the 6 months between her first and second 
skin tests. 
o	 The other explanation is the booster phenomenon. If Ms. Wilson was infected 
with M. tuberculosis many years ago, her ability to react to tuberculin may 
have decreased. This would explain why she did not react to the first TST. 
Then the first tuberculin test may have boosted the ability of her immune 
system to react to tuberculin. This would explain why she had a positive 
reaction to the second TST, which was given within a year of the first test. If 
this scenario is true, Ms. Wilson’s positive reaction would not mean that she 
was recently infected with M. tuberculosis. 
This problem in interpreting Ms. Wilson’s reaction would have been avoided if she had been 
tested with a two-step procedure when she first joined the hospital. In any event, because 





Targeted Testing and the Diagnosis of 










3.5.	 Mr. Lee has a cough and other symptoms of TB disease, and he is evaluated with a 
chest x-ray. However, he is unable to cough up any sputum on his own for the 
bacteriologic examination. 
	 What should be done? 
If a patient cannot cough up a sputum specimen, other techniques can be used to 
obtain sputum. First, clinicians can try to obtain an induced sputum sample. If they 
cannot obtain an induced sputum sample, a bronchoscopy or gastric washing may be 
done. 
3.6.	 Ms. Thompson gave three sputum specimens, which were sent to the laboratory for 
smear examination and culture. The smear results were reported as 4+, 3+, and 4+.  
	 What do these results tell you about Ms. Thompson’s diagnosis and her 
infectiousness? 
These results show that Ms. Thompson’s sputum specimens contain many acid-fast 
bacilli. Because the smears are positive, clinicians should suspect that Ms. Thompson 
has TB disease. They should also consider her infectious. However, it is possible that 
these acid-fast bacilli are mycobacteria other than tubercle bacilli. Therefore, the 
diagnosis of TB disease cannot be proven until the culture results are available. 
3.7.	 Mr. Sagoo has symptoms of TB disease and a cavity on his chest x-ray, but all of his 
sputum smears are negative for acid-fast bacilli.  

 Does this rule out the diagnosis of pulmonary TB disease? 

No. 
	 Why or why not? 
M. tuberculosis may grow in the cultures even though there were no acid-fast bacilli 
on the smear. Mr. Sagoo’s symptoms and his abnormal chest x-ray suggest that he 
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Latent Tuberculosis Infection and Tuberculosis Disease 
3.8.	 In the public health clinic, you see a patient, Ms. Sanchez, who complains of weight 
loss, fever, and a cough of 4 weeks’ duration. When questioned, she reports that she 
has been treated for TB disease in the past and that she occasionally injects heroin. 
 What parts of Ms. Sanchez’s medical history lead you to suspect TB disease? 
Ms. Sanchez has symptoms of TB disease (weight loss, fever, and a persistent cough). 
Also, in the past she has been treated for TB disease. We don’t know whether she 
completed therapy, but until we can prove otherwise, we should assume that she has
TB disease again. Her history of injecting illegal drugs (heroin) is another risk factor 
for TB. 
 What diagnostic tests should be done? 
People who have TB symptoms should be evaluated for TB disease. Because she has 
symptoms of pulmonary TB disease (coughing), Ms. Sanchez should be given a chest 
x-ray. In addition, a sputum specimen should be collected for smear and culture, and 
drug susceptibility testing should be done if the culture is positive for 
M. tuberculosis.. 
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